HIV Medicine Association

01/27/2026

HIVMA’s latest policy brief highlights recommendations for state policymakers to reform prior authorization requirements, improving access to HIV medications and reducing health care costs.

Read the brief:

01/25/2026

We want to hear from you. IDSA and HIVMA are collecting stories about the realities of working in infectious diseases and HIV today and how the current administration is impacting your work and patients.

Advocates interested in sharing their experiences are encouraged to participate. Learn more:

Infectious Diseases Society of America

01/22/2026

In a new TheBody.com article, IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, stresses that despite a tough year for HIV and public health, advances in long-acting PrEP, antibodies, and vaccines offer real hope for 2026.

Despite the devastation of the past year, the collective efforts to lift the voices of the HIV Community have not been stopped. Nearly all threats to HIV-related services are met with organizing and direct political engagement, from the state houses to the U.S. Capitol.

01/21/2026

🚨DEADLINE APPROACHING: Lives are at risk and health care expenses will increase if Congress fails to pass a fiscal year 2026 LHHS funding bill that fully funds federal HIV programs.

Contact your legislators between now and Jan. 30 and urge them to pass FY26 spending bills that safeguard HIV care:

Urge your members of Congress to fully fund federal HIV programs as they negotiate final funding levels for the FY 2026 LHHS spending bill.

01/18/2026

Explore clinical training opportunities through HIVMA’s online directory for physicians, nurse practitioners, physician assistants and pharmacists: https://www.hivma.org/education--training/training--curriculum/hiv-training-programs2/

01/16/2026

Join IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, for the upcoming AVAC webinar, “The Future of Prevention: A People’s Research Agenda for Speed, Scale and Equity,” on Tuesday, Jan. 20 at 9am ET.

Register: https://bit.ly/4aW6Xxi

01/14/2026

"The abrupt termination of Substance Abuse and Mental Health Services Administration grants supporting mental health and substance use services for people with HIV and hepatitis C in communities across America will have far-reaching health and economic consequences. Eroding our country’s mental health and substance use prevention and treatment infrastructure will lead to a dramatic rise in HIV and hepatitis C transmissions and many more HIV and hepatitis C outbreaks.

The withdrawal of this funding puts people’s lives at risk and will lead to a dramatic rise in health care costs as more people require HIV and hepatitis C treatment. We call for the immediate reinstatement of all of the SAMHSA grants."

— Anna K. Person, MD, FIDSA — Chair, HIVMA

01/13/2026

Congress is finalizing Fiscal Year 2026 spending by Jan. 30, and your voice is critical to protecting access to affordable, lifesaving HIV care.

Call your legislators between now and Jan. 30 and urge them to pass FY26 spending bills that safeguard HIV care. Get talking points and a simple call script here:

Overview Congress is working to finalize Fiscal Year 2026 spending by January 30, 2026. Please help ensure access to critical and affordable HIV care by urging Congress to pass: Maintaining access to…

01/09/2026

The House is proposing nearly $2 billion cuts in federal HIV funding, wiping out CDC’s HIV prevention program, core Ryan White services, and the Ending the HIV Epidemic initiative.

Contact your representatives and senators to urge them to fully fund federal HIV programs:

Urge your members of Congress to fully fund federal HIV programs as they negotiate final funding levels for the FY 2026 LHHS spending bill.

01/08/2026

Advocacy is more critical than ever. Identify opportunities and learn storytelling-based communication strategies with the on-demand session, “Courage Is Contagious: Become an Advocate for Change in Challenging Times.”

Available to stream with your registration through March 31: https://cdmcd.co/k96vKK

01/06/2026

NIH’s panel on the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV recently shared major revisions to guidelines on Candida infections, HPV disease, Pneumocystis pneumonia and toxoplasmosis.

See the revisions and send feedback by Jan. 12: https://bit.ly/49awQIv

View updates to the clinical guidelines for opportunistic infections in children with and exposed to HIV.

01/01/2026

Happy New Year! 🎉 2026 marks 25 years of the HIV Medicine Association’s work as a community of health care professionals advancing a comprehensive and humane response to the HIV pandemic, informed by science and social justice.

We are honored to continue this work together in 2026 and beyond.